Koji Ishikawa Takashi Nagai Koki Tsuchiya Yusuke Oshita Takuma Kuroda Hiroshi Ito Soji Tani Yusuke Dodo Tomoaki Toyone Katsunori Inagaki
10.2147/CIA.S180614
Clin Interv Aging
2018 Oct 8;13:1929-1934.
denosumab high bone turnover no renal impairment symptomatic hypocalcemia
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/30349211/
Bone Density Conservation Agents / adverse effects Bone Remodeling Denosumab / adverse effects Hypocalcemia / chemically induced Osteoporosis / drug therapy
Bone Density Conservation Agents / adverse effects Bone Remodeling Denosumab / adverse effects Hypocalcemia / chemically induced Osteoporosis / drug therapy Case Reports Aged Humans Male Risk Factors Vitamin D / therapeutic use Bone Density Conservation Agents Vitamin D Denosumab
PMC6183698
30349211
High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis
2018